Assertion: actinium's product candidate | /r/HasProperty | iomab-b
Facets:
Source sentences:
text: Actinium intends to use the net proceeds from the offering to complete its ongoing pivotal, Phase 3 SIERRA trial for its lead product candidate, Iomab-B, and support its BLA filing.
text: Actinium intends to use the net proceeds from the offering to complete its ongoing pivotal, Phase 3 SIERRA trial for its lead product candidate, Iomab-B, and progress Phase 1 trials from its refocused CD33 program to the proof of concept stage.
text: Actinium intends to use the net proceeds from the offering to complete its ongoing pivotal, Phase 3 SIERRA trial for its lead product candidate, Iomab-B, and support its BLA filing.
text: Actinium intends to use the net proceeds from the offering to complete its ongoing pivotal, Phase 3 SIERRA trial for its lead product candidate, Iomab-B, and progress Phase 1 trials from its refocused CD33 program to the proof of concept stage.
text: Actinium intends to use the net proceeds from the offering to complete its ongoing pivotal, Phase 3 SIERRA trial for its lead product candidate, Iomab-B, and support its BLA filing.
text: Under its sponsorship, Actinium Pharmaceuticals has three product candidates in active clinical trials: Iomab-B (BC8-I-131), Actimab-A and Actimab-M (HuM195-Ac-225.
text: Actinium intends to use the net proceeds from the offering to complete its ongoing pivotal, Phase 3 SIERRA trial for its lead product candidate, Iomab-B, and support its BLA filing.